Biocept's patented Target Selector™ technology enables new specimen type--cerebrospinal fluid (CSF)--to identify biomarkers that can aid physicians in making treatment decisions SAN DIEGO , Jan. 14, 2020 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy
SAN DIEGO --(BUSINESS WIRE)--Jul. 13, 2023-- Biocept, Inc . (Nasdaq: BIOC) (“Biocept” or the “Company”) announces that M. Faye Wilson , Board Chair, passed away unexpectedly on Monday, July 10 . The Board of Directors and staff of Biocept extend their deepest condolences to the Wilson family and
Biocept's patented Target Selector™ test for identification of TRK proteins enables physicians to rapidly and cost-effectively identify the potential presence of NTRK fusions used to inform on treatment options SAN DIEGO , Nov. 21, 2019 /PRNewswire/ -- Biocept, Inc.
Further expands Company's patent portfolio in pursuit of worldwide intellectual property protection for Primer-Switch technology for the field of oncology SAN DIEGO , Sept. 23, 2020 /PRNewswire/ -- Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of liquid biopsy tests designed to
SAN DIEGO , June 22, 2020 /PRNewswire/ -- Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients with cancer, announces the availability of 10,000
Two-year evaluation in advanced lung cancers at Allegheny Health Network demonstrated improved access to optimal treatment while reducing healthcare costs SAN DIEGO , Sept. 21, 2020 /PRNewswire/ -- Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to
SAN DIEGO --(BUSINESS WIRE)--Aug. 22, 2022-- Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that it received a notice (the “Notice”) on August 17, 2022 from the Listing Qualifications Department of The Nasdaq Stock Market LLC
SAN DIEGO , Dec. 6, 2017 /PRNewswire/ -- Biocept, Inc . (NASDAQ: BIOC) (" Biocept " or the "Company"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, today announced that it has
